Alba Torres-Vidal
Barcelona, CT 08028, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Bispecific sigma-1 receptor antagonism and mu-opioid receptor partial agonism: WLB-73502, an analgesic with improved efficacy and safety profile compared to strong opioids.
Journal: Acta pharmaceutica Sinica. B
Published: April 13, 2022
Tricyclic Triazoles as σ1 Receptor Antagonists for Treating Pain.
Journal: Journal of medicinal chemistry
Published: April 07, 2021
EST64454: a Highly Soluble σ1 Receptor Antagonist Clinical Candidate for Pain Management.
Journal: Journal of medicinal chemistry
Published: November 25, 2020
Discovery of EST73502, a Dual μ-Opioid Receptor Agonist and σ1 Receptor Antagonist Clinical Candidate for the Treatment of Pain.
Journal: Journal of medicinal chemistry
Published: October 16, 2020
4-Aryl-1-oxa-4,9-diazaspiro[5.5]undecane Derivatives as Dual μ-Opioid Receptor Agonists and σ1 Receptor Antagonists for the Treatment of Pain.
Journal: Journal of medicinal chemistry
Published: November 20, 2019
Supraspinal and Peripheral, but Not Intrathecal, σ1R Blockade by S1RA Enhances Morphine Antinociception.
Journal: Frontiers in pharmacology
Published: January 23, 2019
Effects of the selective sigma-1 receptor antagonist S1RA on formalin-induced pain behavior and neurotransmitter release in the spinal cord in rats.
Journal: Journal of neurochemistry
Published: August 01, 2013
Sigma-1 receptor antagonism as opioid adjuvant strategy: enhancement of opioid antinociception without increasing adverse effects.
Journal: European journal of pharmacology
Published: November 26, 2012
Evaluation of formalin-induced pain behavior and glutamate release in the spinal dorsal horn using in vivo microdialysis in conscious rats.
Journal: Journal of pharmacological sciences
Published: September 19, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026